Prof. Dr. Harald Gießen from the Institute of Physics (4) as well as Prof. Dr. Alois Herkommer and Dr. Simon Thiele from the Institute of Applied Optics at the University of Stuttgart received the Gips Schüle Research Award 2021 on October 19, 2021. The researchers were awarded the prize, which is valued at EUR 50,000.

Expert interview - 31/08/2021

Health Data Scenarios - many possibilities for the future?

The digitization of healthcare is progressing slowly but steadily. In addition to simple telemedical applications, data such as electronic patient records are forming the basis of digitization. The ‘Health Data Scenarios’ project aims to model the future of healthcare data by using scenarios. Lucas Scherdel, Healthcare Innovation Director at DayOne, and Dr. Alexander Fink, founder and CEO of ScMI AG, explain how this will work.

New drugs are intended to help stop viral zoonoses – infections that jump from animals to humans. To study suitable inhibitors, Prof. Dr Christian Klein from the Institute of Pharmacy and Molecular Biotechnology (IPMB) of Heidelberg University is receiving funding in the amount of 450,000 euros from the Volkswagen Foundation.

As a dominant part of southern Germany’s life-science industry hub, Heidelberg will soon have a life-science startup incubator of its own. BioLabs, the premier US network of managed co-working lab space, will open its first German branch in the Heidelberg Innovation Park (hip). On August 16, representatives of city and state governments, BioLabs and the life-science industry celebrated the Heidelberg BioLabs groundbreaking.

Workplace of the future - 10/08/2021

Intelligent body support system for surgery staff

Operating room staff often spend hours in strenuous postures, which has a significant impact on concentration and quality of work. While operating room equipment is increasingly networked, state-of-the-art medical technology, conditions for operating room staff trail way behind. The start-up company Hellstern medical offers an effective solution for serious pain, fatigue and incorrect interventions.

Scientists from the EMBL and the German Cancer Research Center have presented a new method for generating metabolic profiles of individual cells. The method, which combines fluorescence microscopy and a specific form of mass spectroscopy, can analyze over a hundred metabolites and lipids from more than a thousand individual cells per hour. Researchers expect the method to better answer a variety of biomedical questions in the future.

Article - 22/06/2021

Using virtual reality in the clinic to rehabilitate patients with cognitive disorders

Outdated and inadequate methods of neurological rehabilitation are still being used for patients with neurological diseases or injuries – and what’s more, the treatment is usually too late. This is because cognitive training is especially important in the critical phases when the brain is particularly plastic. The Heidelberg-based company living brain proves that early treatment is possible using an extremely innovative method – with concentrated…

Effective drugs for the treatment of diseases of the central nervous system do exist. However, the blood-brain barrier, which protects the brain as the body's control center, makes it especially difficult for therapeutic biomolecules to pass through. Thus, researchers from an international consortium coordinated by the Fraunhofer IGB have spent the last four and a half years developing a novel system in the EU project "N2B-patch"…

The Deep-Tech Start-Up memetis GmbH from Germany, which produces the world’s most compact and lightest commercially available valves driven by shape memory alloys, announces a new partnership with Fluid-o-Tech S.r.l., an Italian innovation and market leader in the field of fluid-pumps.

Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.

Vaccine development - 25/05/2021

Vaccines - a beacon of hope in the fight against pandemics

Having long been considered less lucrative for the big pharmaceutical companies, vaccine development is taking off in an unforeseen way in the wake of the COVID-19 pandemic. Financial support is flooding in and all kinds of vaccine development strategies are being deployed. Among the winners in the competition for effective coronavirus vaccines are vaccines based on RNA technology.

The working group around Dr. Philipp Rathert at the Institute for Biochemistry and Technical Biochemistry investigates the regulation of epigenetic networks of certain cancers and ways of treating them. The working group published its new findings in April.

Genetically enhancing a patient's immune cells by adding therapeutic genes to them outside the body is regarded as a promising new treatment approach in oncology. However, the production of these therapeutic cells using viruses is not only expensive but time-consuming. Researchers at the German Cancer Research Center (DKFZ) have developed an innovative non-viral vector that can efficiently introduce therapeutic genes into immune cells.

Evotec SE announced today the launch of beLAB2122 in the Rhine- Main-Neckar region to efficiently advance first-in-class therapeutic concepts into investable drug discovery projects. Mediated and supported by BioRN, Evotec’s newest BRIDGE brings together the European Molecular Biology Laboratory (“EMBL”), the German Cancer Research Center (“DKFZ”), the Goethe University Frankfurt, Heidelberg University and the University of Tübingen.

Quantum Technology Ulm - 08/04/2021

Diamonds for life sciences innovations

The world's first commercial quantum computer,’IBM Q System One’, is now in operation in Ehningen near Stuttgart. This is a major leap forward in quantum technology in Germany. It marks the point at which conventional computers reach their limits. The University of Ulm is involved in three of six collaborative projects being funded by the Baden-Württemberg Ministry of Economic Affairs, Labour and Housing Construction.

Microfluidics in medical technology - 24/03/2021

Ultra-compact: valves with shape memory actuators

Karlsruhe-based company memetis shows that this is possible. Intelligent components for controlling fluids open up huge potential in the medical technology and biotechnology sectors - from vaccine development and cell line analysis to drug research and point-of-care solutions.

Article - 17/02/2021

Whole blood model enables development of early warning system for sepsis

Sepsis is a life-threatening disease that can be treated all the more successfully the faster therapy is initiated. It is not just the infection itself that is so dangerous, but a dysregulated response of the immune system. Physicians at Ulm University Hospital have now developed an animal-free test system that can be used to research the disease and develop innovative diagnostic tools to quickly assess a patient's sepsis risk and optimise…

In a so-called inactivated or killed vaccine, the virus particles it contains are first rendered inactive by means of the toxic chemical formaldehyde. A better way of achieving this, however, is to irradiate the pathogens with low-energy electrons. Four Fraunhofer Institutes have now developed a new method of vaccine production based on this technique that is not only quicker but also guarantees a higher quality of product.

Lab-on-a-chip - 11/11/2020

Microfluidic platform for the best possible cancer therapy

Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.

Inside the fight against COVID-19 - 28/10/2020

A new immunotherapeutic agent for treating severe COVID-19 cases

Apogenix, a Heidelberg-based biopharmaceutical company specialising in innovative immunotherapeutics, has initiated a Phase II clinical trial with asunercept, the company’s lead drug candidate for treating severe cases of COVID-19. The fusion protein blocks the CD95-ligand-mediated death of epithelial cells in the lung and thus prevents damage to the organ.

Innovative Therapies - 20/08/2020

Labor Dr. Merk is fully committed to viral therapies

Labor Dr. Merk & Kollegen is reorienting its business towards viral therapeutics. With this change of strategy, the company, which has decades of expertise in virology, wants to position itself in a timely fashion in the growing new market for advanced therapy medicinal products (ATMP). In gene and virotherapies (oncolytic viruses), tumour vaccines and CAR-T cell therapies, viruses are essential as vectors, killers of tumour cells or…

Microstructure Technology - 17/07/2020

An electronic nose for many applications

Sensory organs are sophisticated masterpieces of nature. That is why humans have often tried to copy them. Be it cameras or microphones - there are technical objects that have always been based on natural models such as the eye or the ear. For a long time, however, no artificial sense of smell has featured in the technical repertoire. Now researchers at the Karlsruhe Institute of Technology (KIT) have developed an electronic nose. It can…

Review article (new edition) - 08/07/2020

Immunology – at the forefront of medical progress

Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.

SICOS BW GmbH - 18/06/2020

High-performance computing and data analytics to combat coronavirus

In an epidemic, data exchange and the use of innovative technologies are essential to be able to act effectively and quickly against the infection. High-performance computers and data analytics make a valuable contribution to this. SICOS BW is a promising solution centre that bridges the gap from numerical simulation, big data and AI to companies in the medical technology sector.

Innovations in the field of endoscopy - 08/06/2020

Gastroscopies with pill cameras

A pill camera to examine the gastrointestinal tract that can be swallowed without major difficulty, controlled intuitively from the outside and deliver images in real time - why would any doctor or patient say no? To non-experts, it sounds more like science fiction but such a device is actually already in development: since 2019, Tübingen-based Ovesco Endoscopy AG and three partners have been working together on this in a project called nuEndo.

Material research - 25/05/2020

Reaching up into weightlessness – a start-up that enables commercial research experiments in space

Yuri, a start-up company founded in 2019 in the Lake Constance area, is aiming high. The company’s mission is to enable microgravity research into the development of materials, new medicines and vaccines, including research opportunities on the International Space Station (ISS). Yuri’s tailor-made solutions are faster and more affordable than previous space research missions.

Heidelberg Technology Park - 05/05/2020

Start-up support for life sciences companies

How can scientists turn their know-how into marketable products and services and thereby provide society with real added value? In addition to solid financing, start-up companies need a suitable infrastructure and a dense network of partners for exchanging expertise to help them get off to a good start when it comes to setting up a business. The Heidelberg Technology Park offers company founders in the life sciences exactly these success factors.

Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB - 24/04/2020

A rapid pyrogen test: the human immune system as model

Every year, around 11 million people die of sepsis (blood poisoning) caused by microorganisms or microbial residues, known as pyrogens, entering the bloodstream. The smallest amounts can trigger fever. Researchers from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart have developed a pyrogen test that does not require a laboratory and is not tested on animals. It is expected to be placed on the market soon.

Multiple sclerosis - 12/03/2020

Direct application of biopharmaceuticals through the nose into the brain

There is currently no cure for multiple sclerosis, the most common neurological autoimmune disease in humans. Biopharmaceuticals that can delay the course of the disease or diminish its effects are often prevented from being fully effective by the blood-brain barrier. A European consortium led by the Fraunhofer IGB, Stuttgart is developing a new technology that can transport an innovative active ingredient directly to the central nervous system.

Novel coronavirus outbreak - a status report on recent developments - 04/03/2020

Waiting for a SARS-CoV-2 vaccine

Researchers around the world are working frantically on the development of a vaccine against the new coronavirus. A project by the Tübingen-based biotechnology company CureVac, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), uses the company’s technology platform for mRNA-based vaccines to accelerate vaccine development, thus contributing to the future prevention of the disease.

Expert interview - 13/05/2019

Innovation management in the life sciences – Inova DE provides insights

Personalized medicine, medical technology, digital health and artificial intelligence are revolutionizing diagnostics and product development. Analyses are becoming faster and more precise, and data volumes can now be networked and used effectively. The goal of improving people's quality of life is within reach, and this will also strengthen Germany’s future viability. However, not every good idea can be turned into a marketable commodity.…

Article - 03/04/2019

HKK Bionics empowers hand gripping functions

A spin-off from the Ulm University of Applied Sciences is aiming to provide people whose hands have been paralysed due to accident or illness with a new kind of orthopaedic aid. Dominik Hepp and Tobias Knobloch are currently starting serial production of a hand orthosis prototype. The two medical engineers from Ulm, who founded HKK Bionics GmbH in 2017, plan to commence final tests in 2019.

Article - 28/03/2019

Supporting the human use of artificial intelligence

Artificial intelligence is no longer a vision of the future, but is already in our midst: whether it is parking aids or search engines, we use the technology quite naturally in many areas of daily life. It promises new, unlimited opportunities, but also poses risks. Experts from the Integrata Foundation in Tübingen work on ethical issues and the human use of IT for improving the life of as many people as possible.

Article - 22/03/2019

Personalised therapies for treating metastasing breast cancer

Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.

Dossier - 10/11/2014

Cell and gene therapies from bench to bedside

While cell therapy has become standard treatment for a number of blood cancers, most cell and gene therapy approaches for the treatment of hereditary and metabolic diseases, neurodegenerative disorders and cancer are still in the experimental phases or early clinical trials. However, recent successes give rise to the hope that cell and gene therapies will in future make important contributions to previously incurable diseases.

Dossier - 18/11/2013

Innovative textiles made possible by biotechnology

Biotechnology plays a part in many high-tech fabrics that have become an integral part of our everyday life. Whether it is products for the treatment of wounds, fabrics for marquees or for clothing, many materials have been developed or are produced using biotechnological techniques and processes. Many products marketed as “micro” or “nano” are inspired by nature.

Dossier - 04/11/2013

Biotechnology driver of innovation in the pharmaceutical industry

The biotech industry is the innovative driver for a pharmaceutical industry that, due to the shift from blockbluster products to personalised medicine, now depends on new concepts. The production of new drugs using genetic engineering relies on knowledge gained from genomics, proteomics and systems biology and creates new treatment strategies that combine therapy and diagnostics (i.e. companion diagnostics) to provide a specific individualised…

Dossier - 05/08/2013

Progress expands bioethical boundaries

Bioethics is a rich and continually evolving field. In the broadest sense, bioethics relates to the way human individuals treat any form of life. The issue of whether human beings have the right to do whatever they want goes way back. Rapid progress in genetic engineering and cell biology means that it is necessary to look at certain issues in a new way and recognise that not everything that is technically feasible should actually be carried out.

Dossier - 21/05/2013

No new drugs to be placed on the market without clinical trials

New pharmaceuticals are subject to approval by drug authorities. Here clinical trials are performed to ensure the quality efficacy and safety of a medicinal product. Clinical development is a time-consuming and costly process and takes on average ten to fifteen years before a pharmaceutical company can apply for the approval of the drug. The costs including failures can amount to approximately one billion US dollars per drug.

Dossier - 13/05/2013

The human proteome the next major goal

The “Human Proteome Project”, a ten-year global initiative that is making a systematic effort to map all human proteins, has moved from the planning to the experimental stage. How significant and how effective the project will be depends on how much the resources offered are used by proteome researchers and on the data that the researchers bring into the project.

Dossier - 20/12/2012

Medical technology serving healthcare

Modern healthcare would be impossible without medical technology. The achievements in medical technology are indispensable for our health and quality of life. The range of medical technology available covers surgical instruments and implants to diagnostic methods and medical devices.

Dossier - 26/11/2012

Genetic diagnostics technology reaches the limits of what is medically reasonable

Rapid progress in sequencing technologies is poised to set the imagination of biomedical researchers on fire. Experts now believe that progress is about to make possible what seemed to be utopian a few years ago – it seems likely that it will soon be possible to sequence the human genome in only a few minutes and store and automatically analyse it using tiny automates. However, is everything that is technically feasible also reasonable?

Dossier - 10/09/2012

Horizon 2020 the EU framework programme for research and innovation a boost for top-level research in Europe

In the face of the ongoing financial crisis Europe is working on a new research strategy that is aimed at creating new economic growth and jobs. The new EU framework programme for research and innovation Horizon 2020 replaces the 7th Framework Programme FP7 and will run from 2014 with a budget of 80 billion. In July 2012 Brussels launched the final FP7 calls for proposals for 2013 that offer numerous market-based instruments designed to bridge…

Dossier - 12/03/2012

Regenerative medicine makes use of patients own resources

Die Regenerative Medizin bietet neue Therapieoptionen quer durch die ärztlichen Fachgebiete. Zumeist sind es zellbasierte Verfahren und sie werden häufig mit innovativen Biomaterialien kombiniert. Regenerative Therapien vereinen Know-how aus den Biowissenschaften mit moderner Medizintechnik und sie profitieren von den Fortschritten in den Ingenieur- und Materialwissenschaften.